4Richardson PC,Barlogie B,Berensen J. A phase 2 study of bortezomib in relapsed refractory myeloma[J].New England Journal of Medicine,2003,(26):2609-2617.doi:10.1056/NEJMoa030288.
5Orlowski RZ,Stinchcombe TE,Mitchell BS. Phase Ⅰ trial of the preteasome inhibitor PS-341 in patients with refractory hematologic malignancies[J].Journal of Clinical Oncology,2002,(22):4420-4427.doi:10.1200/JCO.2002.01.133.
6Miyakoshi S,Kami M,Yuji K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma[J].Blood,2006,(09):3492-3494.doi:10.1182/blood-2005-11-4541.
7Boyer JE,Batra RB,Ascensao JL. Severe pulmonary complication after bortezomib treatment for multiple myeloma[J].Blood,2006,(03):1113.doi:10.1182/blood-2006-03-011494.
8Engelhardt M,Muller AMS,Maier W. Severe irreversible bilateral hearing less after bortezomib (VELCADEs) therapy in a multiple myeloma (MM) patient[J].Leukemia:Official Journal of the Leukemia Society of America Leukemia Research Fund U K,2005,(05):869-870.
9Resi(n)ol L,Montoto S,Cibeira MT. Bortezomib-induced severe hepatitis in multiple myeloma[J].Archives of Internal Medicine,2005,(04):464-465.doi:10.1001/archinte.165.4.464.
10Kenealy MK,Prince HM,H(o)nemann D. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma[J].Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy,2006,(08):1205-1206.
